Introduction {#s1}
============

The purpose of this ancillary study was to determine if the risk for diabetes complications in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) glycemia trial differed among individuals with lower or higher HbA~1c~ levels than predicted by fasting plasma glucose (FPG). ACCORD participants were middle-aged and older people with type 2 diabetes and established cardiovascular disease (CVD) or known cardiovascular risk factors ([@B1]). The trial tested whether intensive treatment targeting HbA~1c~ levels of less than 6% (42 mmol/mol) would reduce the rate of cardiovascular events compared with a strategy targeting HbA~1c~ levels between 7.0% and 7.9% (53 and 63 mmol/mol). This hypothesis was not supported: Intensive treatment failed to improve primary cardiovascular outcomes and was instead associated with 22% greater total mortality compared with standard treatment. The ACCORD trial thus demonstrated that increased mortality was a previously unrecognized harm of intensive glucose-lowering therapy in high-risk patients with type 2 diabetes. Although symptomatic severe hypoglycemia was associated with an increased risk of death in the intensive and standard treatment groups, differences in HbA~1c~ or rates of hypoglycemia between the two groups did not explain the greater mortality observed in the intensive-treatment group ([@B2]).

Treating patients with diabetes with drugs that lower blood glucose levels inherently increases the risk for hypoglycemia. Intensively treating patients with diabetes to a low HbA~1c~ target implicitly assumes that all patients will have roughly the same blood glucose level when they reach the target. Miller et al. ([@B3]) paradoxically reported that ACCORD participants with higher HbA~1c~ levels had greater risk for hypoglycemia. If HbA~1c~ were an unbiased estimate of blood glucose, this observation would incongruously suggest that participants with higher blood glucose levels had greater risk for hypoglycemia. Numerous studies have shown, however, that some patients with diabetes have HbA~1c~ levels that are persistently lower or higher than predicted compared with other individuals with similar blood glucose levels ([@B4]--[@B10]).

We reasoned that intensive treatment to a one-size-fits-all HbA~1c~ target of less than 6% (42 mmol/mol) may have inadvertently and disproportionately produced adverse outcomes in a subgroup of ACCORD patients with diabetes with lower blood glucose levels than their HbA~1c~ would predict. To test this hypothesis, we used the hemoglobin glycation index (HGI) to identify ACCORD participants with incongruous HbA~1c~ and FPG at baseline. HGI is the calculated difference between an individual's observed HbA~1c~ and a predicted HbA~1c~ derived by inserting the individual's blood glucose concentration into a population regression equation describing the linear relationship between HbA~1c~ and blood glucose (HGI = observed HbA~1c~ − predicted HbA~1c~) ([@B4],[@B9]).

Assessment of HGI in the Diabetes Control and Complications Trial (DCCT) showed that patients with type 1 diabetes with a high HGI had a threefold greater risk for retinopathy and a sixfold greater risk for nephropathy ([@B6]). Most prior HGI research calculated predicted HbA~1c~ based on mean blood glucose (self-monitored ([@B4],[@B9]), timed profiles ([@B6]), or continuous glucose monitoring ([@B11])). HGIs calculated using all glucose data downloaded from patient meters were highly correlated with HGIs calculated using only prebreakfast glucose data ([@B4]). The feasibility of using FPG to calculate the HGI in patients with type 2 diabetes was previously proposed ([@B12]). The glycation gap developed by Cohen et al. ([@B5]) is calculated in exactly the same way as HGI except fructosamine replaces directly measured glucose for obtaining a predicted HbA~1c~. Several studies have shown that patients with type 2 diabetes with a high glycation gap have greater risk for microvascular or macrovascular complications ([@B5],[@B10],[@B13],[@B14]). HGI and the glycation gap are strongly positively correlated, which suggests they reflect the same biological phenomenon ([@B15]).

Patients with diabetes with low and high HGI have HbA~1c~ levels that are lower or higher than predicted, respectively, compared with other patients with similar blood glucose levels. We hypothesized that intensive treatment produced disproportionately lower blood glucose levels and increased hypoglycemia in the subgroup of ACCORD participants with a high HGI. This could explain the otherwise paradoxical results reported by Miller et al. ([@B3]). Also, higher baseline HbA~1c~ and higher average on-treatment HbA~1c~ were both strong predictors of mortality associated with intensive treatment in ACCORD ([@B16],[@B17]). Because HGI was associated with increased complications risk in patients with type 1 diabetes in the DCCT, we also hypothesized that patients with type 2 diabetes with high HGI in ACCORD might also have a greater risk for primary cardiovascular outcomes, total mortality, and microvascular disease.

Research Design and Methods {#s2}
===========================

This research was approved by the institutional review boards at the Louisiana State University Health Sciences Center and Children's Hospital, New Orleans, LA.

ACCORD Study Design {#s3}
-------------------

ACCORD was a multicenter, randomized clinical trial that used a double 2 × 2 factorial design to incorporate intervention trials for glycemia, hyperlipidemia, and hypertension. The lipid intervention trial tested in 5,518 participants the hypothesis that a hypolipidemic agent would improve outcomes in subjects with good glycemic control. The blood pressure intervention trial tested in the remaining 4,733 participants the hypothesis that a therapeutic strategy that targets a systolic blood pressure of \<120 mmHg will reduce the rate of CVD events compared with a strategy that targets a systolic blood pressure of \<140 mmHg. All participants enrolled in the ACCORD trial had type 2 diabetes and had experienced a prior cardiovascular event or had other evidence of high risk for CVD. Median follow-up time was 5.0 years (mean 5.0; range 0.01--8.4). The rationale, study design, inclusion criteria, and other details of the ACCORD trial are described elsewhere ([@B1],[@B18]--[@B20]).

The glycemia intervention trial included all 10,251 ACCORD participants, who were randomly assigned at baseline to a standard treatment group or an intensive treatment group. Any antihyperglycemic agent or combination of agents approved by regulatory authorities could be used as considered appropriate to achieve protocol-mandated target HbA~1c~ levels of 7.0% to 7.9% (53 to 63 mmol/mol) in the standard treatment group, or less than 6.0% (42 mmol/mol) in the intensive treatment group. During the trial, excess mortality was demonstrated at 3.5 years of average follow-up, at which time all participants in the intensive treatment group were converted to the standard treatment regimen ([@B20]). Data for this ancillary study were obtained from the ACCORD coordinating center on all enrolled participants. Only data from participants with FPG and HbA~1c~ recorded at baseline (*n* = 10,125) were used in these analyses.

Primary and Secondary Outcomes {#s4}
------------------------------

The prespecified primary outcome for ACCORD was a composite of the first occurrence of nonfatal myocardial infarction (MI), nonfatal stroke, or death from cardiovascular causes ([@B18]). Causes of cardiovascular death included fatal MI, congestive heart failure, documented arrhythmia, death after invasive cardiovascular interventions, death after noncardiovascular surgery, fatal stroke, unexpected death due to ischemic CVD occurring less than 24 h after the onset of symptoms, and death due to other vascular diseases such as pulmonary emboli or abdominal aortic aneurysm rupture. Death from any cause was one of several prespecified secondary outcomes ([@B1]). Primary and secondary outcomes were assessed from baseline through the last set of scheduled study visits (March--June 2009) ([@B20]).

Definition of Severe Hypoglycemia {#s5}
---------------------------------

Symptomatic, severe hypoglycemia requiring any assistance was defined as an episode of hypoglycemia with a documented blood glucose concentration of less than 50 mg/dL (2.8 mmol/L) in which the participant reported receiving medical care or assistance from another individual or recovery with carbohydrate treatment. Symptomatic, severe hypoglycemia requiring medical assistance was defined as an episode of hypoglycemia in which the participant received care at a hospital or emergency department or from medical personnel. Hypoglycemia assessment included hypoglycemia events from baseline up to the transition period when intensive glycemic intervention was terminated (February 2008).

Deriving HGI from the HbA~1c~ Versus FPG Regression Equation {#s6}
------------------------------------------------------------

Baseline FPG and HbA~1c~ data from a random subsample of 1,000 ACCORD participants were used to estimate the linear relationship between FPG and HbA~1c~ in the study population. A predicted HbA~1c~ was calculated for the remaining 9,125 participants by inserting the baseline FPG into the subsample linear regression equation (HbA~1c~ = 0.009 FPG \[mg/dL\] + 6.8). Baseline HGI was calculated by subtracting the predicted HbA~1c~ from the observed HbA~1c~. The 9,125 participants were then assigned to low, moderate, or high HGI subgroups based on baseline HGI and HGI cut points that divided the population into three equally sized subgroups (low HGI ≤ −0.520 \[*n* = 3,041\], 33.3%; moderate HGI −0.520 to 0.202 \[*n* = 3,042\], 33.3%; high HGI \>0.202 \[*n* = 3,042\], 33.3%). The use of a tertile classification system is by convention for consistency with previous HGI studies. We compared HGI classifications using simple linear regression with HGI classifications based on cubic spline regression and observed more than 90% identity. We chose the linear regression model because this approach is simpler and has precedent.

Statistical Analysis {#s7}
--------------------

Baseline characteristics and other variables were compared among low, moderate, and high HGI subgroups. Group comparisons used ANOVA or Kruskal-Wallis tests for normally distributed and nonnormally distributed continuous variables, respectively, and χ^2^ tests were used for categorical variables. Kaplan-Meier curves and log-rank tests were used to compare the distribution of time to first event. Post hoc analyses were performed to compare risk of primary outcomes, total mortality, and hypoglycemia between the intensive and standard glycemia treatment groups and among HGI subgroups with adjustment for covariates. Hazard ratios and 95% CI were determined by stratified Cox proportional hazards regression models. Tests of statistical significance were based on a two-tailed type 1 error at *P* \< 0.05. The interaction term of HGI subgroup with glycemia treatment was added to each model, and a likelihood ratio test was applied. Whenever the interaction test did not meet the criteria for statistical significance, a Bonferroni correction for multiple comparisons was applied when evaluating the effect of treatment by subgroup. Proportional hazards assumptions were assessed by cumulative sums martingale residuals over follow-up times using Kolmogorov-type supremum tests and no violation was found.

Covariates included baseline characteristics, study location among the seven clinical-center networks, and for other ACCORD intervention assignments (the blood pressure trial, assignment to the intensive blood pressure intervention group, or the lipid trial, assignment to receive fibrate in the lipid trial). Sensitivity analyses were performed to determine hazard ratio stability after including intervention assignments in the Cox model as stratifying factors rather than as covariates. Baseline characteristics were age, sex, ethnicity, education level, medical history (smoking history, duration of diabetes, retinopathy detected at baseline, history of CVD, high risk of congestive heart failure, evidence of significant atherosclerosis, albuminuria), and laboratory and clinical measures at baseline (FPG, diastolic blood pressure, estimated glomerular filtration rate, LDL-cholesterol, HDL-cholesterol, and triglycerides). Outcomes based on Cox regression models were similar to those obtained using logistic regression. We used Cox regression in reporting our results to account for the fact that ACCORD participants were monitored for different lengths of time, leading to a changing denominator over time that is not adequately modeled by the constant average denominator imposed by the logistic model. Statistical analyses were performed using SAS 9.3 or STATA 13 software.

Results {#s8}
=======

[Figure 1*C*](#F1){ref-type="fig"} shows the linear relationship between HbA~1c~ and FPG in the ACCORD population at baseline. [Figure 1*A* and *B*](#F1){ref-type="fig"} shows that the frequency distribution of HbA~1c~ was markedly different in the low, moderate, and high HGI subgroups. In contrast, FPG distribution was similar among the subgroups. Selected baseline demographic, biochemical, and clinical characteristics are compared among the HGI subgroups in [Table 1](#T1){ref-type="table"}. Of particular note, there were disproportionately more black and Hispanic participants and fewer white participants in the high HGI subgroup. Furthermore, high HGI participants were younger, had longer duration of diabetes, were more likely to already have retinopathy and a history of albuminuria at baseline, and were more likely to have used insulin before the start of the study.

![Assessment of HbA~1c~ and FPG at baseline. The low, moderate, and high HGI subgroups have green, blue, or red lines, respectively. *A*: Distribution of HbA~1c~ by HGI subgroup. *B*: Distribution of FPG by HGI subgroup. *C*: The red dotted line is the simple linear population regression line.](dc141844f1){#F1}

###### 

Baseline characteristics of ACCORD participants by HGI subgroup

                                                Low HGI        Moderate HGI   High HGI       
  --------------------------------------------- -------------- -------------- -------------- ---------
  HbA~1c~ (%)                                   7.4 ± 0.5      8.1 ± 0.5      9.4 ± 0.9      \<0.001
  Median HbA~1c~ (%)                            7.4            8.1            9.2            
  HbA~1c~ (mmol/mol)                            57.4 ± 18.0    65.0 ± 18.0    79.2 ± 13.7    
  FPG (mg/dL)                                   178.5 ± 52.3   169.0 ± 51     178.3 ± 64.2   \<0.001
  FPG (mmol/L)                                  9.9 ± 2.9      9.4 ± 2.8      9.9 ± 3.6      
  HGI (%)                                       −0.961 ± 0.4   −0.183 ± 0.2   0.996 ± 0.7    \<0.001
  Age (years)                                   62.6 ± 6.8     62.7 ± 6.9     61.5 ± 6.8     \<0.001
  Median \[IQR\] duration of diabetes (years)   8 \[10\]       10 \[10\]      10 \[11\]      \<0.001
  Female sex                                    1,072 (35.3)   1,196 (39.3)   1,235 (40.6)   \<0.001
  Race or ethnic group (group %)                                                             \<0.001
   White                                        2,148 (37.6)   1,957 (34.3)   1,606 (28.1)   
   Black                                        375 (21.7)     551 (31.9)     799 (46.3)     
   Hispanic                                     162 (24.9)     211 (32.5)     277 (42.6)     
   Other                                        356 (34.3)     323 (31.1)     360 (34.6)     
  Education                                                                                  \<0.001
   Less than high school                        377 (12.4)     438 (14.4)     523 (17.2)     
   High school graduate                         773 (25.4)     800 (26.3)     825 (27.1)     
   Some college                                 1,017 (33.5)   1,035 (34.1)   950 (31.3)     
   College degree or higher                     872 (28.7)     767 (25.2)     742 (24.4)     
  Cigarette smoking status                                                                   \<0.01
   Current                                      399 (13.1)     437 (14.4)     452 (14.9)     
   Former                                       1,415 (46.6)   1,348 (44.3)   1,271 (41.9)   
   Never                                        1,223 (40.3)   1,255 (41.3)   1,314 (43.3)   
  Alcohol use                                   798 (26.3)     755 (24.8)     640 (21.1)     \<0.001
  Insulin use                                   835 (27.5)     1,036 (34.1)   1,321 (43.4)   \<0.001
  Metformin use                                 1,887 (62.1)   1,877 (61.7)   1,681 (55.3)   \<0.001
  Sulfonylurea use                              1,576 (51.8)   1,584 (52.1)   1,433 (47.1)   \<0.001
  Thiazolidinedione use                         595 (19.6)     645 (21.2)     538 (17.7)     0.025
  History of hypertension                       2,856 (93.9)   2,864 (94.2)   2,837 (93.3)   0.33
  Previous CVD                                  1,014 (33.3)   1,114 (36.6)   1,085 (35.7)   0.02
  High risk of heart failure                    75 (2.5)       70 (2.3)       69 (2.3)       0.86
  History of albuminuria                        944 (31.0)     990 (32.5)     1,133 (37.3)   \<0.001
  History of left ventricular hypertrophy       125 (4.1)      107 (3.5)      151 (5)        0.02
  History of arterial stenosis                  141 (4.6)      158 (5.2)      157 (5.2)      0.53
  Retinopathy at baseline                       697 (22.9)     819 (26.9)     883 (29.0)     \<0.001
  Neuropathy at baseline                        1,889 (62.2)   1,951 (64.3)   1,920 (63.1)   0.25
  Serum creatinine (mg/dL)                      0.9 ± 0.2      0.9 ± 0.2      0.9 ± 0.2      0.12
  Estimated GFR (mL/min/1.73 m^2^)              89.7 ± 27.8    90.8 ± 24.8    92.8 ± 29      \<0.001
  Cholesterol (mg/dL)                                                                        
   Total                                        180.3 ± 39.5   182.3 ± 41.6   187 ± 44       \<0.001
   LDL                                          101.1 ± 32     104.4 ± 33.7   108.6 ± 35.3   \<0.001
   HDL                                                                                       
    Men                                         38.6 ± 9.8     38.2 ± 8.9     39.0 ± 10.0    \<0.001
    Women                                       46.7 ± 12.0    46.7 ± 12.7    47.9 ± 13.1    \<0.001
  Median \[IQR\] triglycerides (mg/dL)          160 \[126\]    155 \[120\]    149 \[122\]    \<0.001
  Blood pressure (mmHg)                                                                      
   Diastolic                                    74.8 ± 10.7    74.3 ± 10.6    75.4 ± 10.7    \<0.001
   Systolic                                     136 ± 16.6     136.2 ± 17.1   136.8 ± 17.6   0.21
  BMI (kg/m^2^)                                 32.2 ± 5.4     32.3 ± 5.4     32.2 ± 5.6     0.56
  Waist circumference (cm)                      107 ± 13.8     107.1 ± 13.9   106.4 ± 14.1   0.15

GFR, glomerular filtration rate; IQR, interquartile range.

^a^Unless otherwise noted, values are means ± SD for continuous variables or number (%) for categorical variables. ^b^Overall differences between HGI groups using ANOVA, Kruskal-Wallis tests, or χ^2^ tests.

After 1 year of standard ([Fig. 2*A*](#F2){ref-type="fig"}) or intensive ([Fig. 2*B*](#F2){ref-type="fig"}) treatment, mean HbA~1c~ remained significantly different (*P* \< 0.001) between HGI subgroups and was highest in the high HGI subgroup. In contrast, the mean FPG was significantly lower (*P* \< 0.001) in the moderate and high HGI subgroups after 1 year of standard treatment ([Fig. 2*A*](#F2){ref-type="fig"}) and was not different (*P* \> 0.05) between HGI subgroups after 1 year of intensive treatment ([Fig. 2*B*](#F2){ref-type="fig"}). The number of participants above or below the HbA~1c~ intensification thresholds varied after 1 year in the standard treatment arm: 43.0% of high HGI participants remained above the 8% (64 mmol/mol) intensification threshold compared with only 30.6% of moderate and 21.9% of low HGI participants. After 1 year in the intensive treatment arm, 88.7% of high HGI participants remained above the 6% (42 mmol/mol) intensification threshold compared with 83.9% of moderate and 72.7% of low HGI participants. Barring mitigating circumstances, such as a recent hypoglycemic event, having disproportionately more participants above the intensification threshold should have resulted in greater treatment intensification at the 1-year visit.

![HbA~1c~ and FPG disparity among HGI subgroups. Mean (± 95% CI) HbA~1c~ (□) and FPG levels (■) for low, moderate, and high HGI subgroups after 1 year of standard (*A*) or intensive (*B*) glycemia treatment. For each panel, HbA~1c~ or FPG values with different superscripts (a, b, c) are significantly different (*P* \< 0.05). The dotted lines denote protocol-mandated HbA~1c~ treatment-intensification thresholds.](dc141844f2){#F2}

Kaplan-Meier ([Fig. 3](#F3){ref-type="fig"}) and Cox regression analyses ([Table 2](#T2){ref-type="table"}) show that the effect of intensive treatment differed markedly among the HGI subgroups. For example, if we ignore HGI, the event rate for primary outcomes was not significantly different (*P* = 0.09) between the intensive (9.8%) and standard (10.7%) treatment groups ([Table 2](#T2){ref-type="table"} and [Fig. 3*A*](#F3){ref-type="fig"}). A statistically significant interaction was detected between treatment and HGI (*P* = 0.0091). Subsequent HGI subgroup analysis showed that intensive treatment reduced primary outcomes by 25% (*P* = 0.02) in the low HGI subgroup and by 23% (*P* = 0.02) in the moderate HGI subgroup ([Table 2](#T2){ref-type="table"} and [Fig. 3*B*](#F3){ref-type="fig"}). In contrast, primary outcomes in the high HGI subgroup were not significantly different between the standard and intensive glycemia treatment groups (*P* = 0.20).

![Kaplan-Meier curves for primary outcomes, total mortality, and hypoglycemia requiring any assistance. Proportions of participants free of the specified outcome over time are compared between standard and intensive treatment groups (panels *A*, *C*, *D*) and among the HGI subgroups (panels *B*, *D*, *F*). Standard treatment is depicted by orange dashed lines and intensive treatment by solid purple lines. Low, moderate, and high HGI subgroups have green, blue, or red lines, respectively.](dc141844f3){#F3}

###### 

Risk and adjusted hazard ratios of composite primary outcomes, total mortality, and hypoglycemia by glycemia treatment group and HGI subgroup

                                                                 Intensive treatment (I)   Standard treatment (S)   Adjusted hazard ratio (I/S)   Interaction between treatment and HGI                                                                            
  --------------------------------------------------- ---------- ------------------------- ------------------------ ----------------------------- --------------------------------------- ----- ------ ------ ------------ --------------------------------------- --------------------------------------
  Primary outcomes[^a^](#t2n1){ref-type="table-fn"}   Overall    4,570                     446                      9.8                           4,555                                   487   10.7   0.89   0.97--1.02   0.09                                    
                                                      Low        1,532                     119                      7.8                           1,509                                   147   9.7    0.75   0.59--0.95   0.02                                    0.0091
                                                      Moderate   1,515                     128                      8.4                           1,527                                   161   10.5   0.77   0.61--0.97   0.02                                    
                                                      High       1,523                     199                      13.1                          1,519                                   179   11.8   1.14   0.93--1.40   0.20                                    
  Total mortality[^b^](#t2n2){ref-type="table-fn"}    Overall    4,570                     350                      7.7                           4,555                                   287   6.3    1.21   1.04--1.42   0.02                                     
                                                      Low        1,532                     97                       6.3                           1,509                                   86    5.7    1.08   0.81--1.44   1.00[^d^](#t2n4){ref-type="table-fn"}   0.2240[](#t2n4){ref-type="table-fn"}
                                                      Moderate   1,515                     102                      6.7                           1,527                                   92    6.0    1.06   0.80--1.41   1.00[^d^](#t2n4){ref-type="table-fn"}   
                                                      High       1,523                     151                      9.9                           1,519                                   109   7.2    1.41   1.10--1.81   0.02[^d^](#t2n4){ref-type="table-fn"}   
  Hypoglycemia[^c^](#t2n3){ref-type="table-fn"}       Overall    4,570                     763                      16.7                          4,555                                   238   5.2    3.64   3.14--4.21   \<0.001                                 
                                                      Low        1,532                     222                      14.5                          1,509                                   56    3.7    4.27   3.21--5.78   \<0.001                                 0.0350
                                                      Moderate   1,515                     254                      16.8                          1,527                                   68    4.5    4.32   3.32--5.68   \<0.001                                 
                                                      High       1,523                     287                      18.8                          1,519                                   114   7.5    2.91   2.35--3.63   \<0.001                                 

^a^First occurrence of nonfatal MI, nonfatal stroke, or death from cardiovascular events. Covariates include age, sex, race, education, diabetes duration, history of smoking, previous CVD, high risk of heart failure, history of arterial stenosis, history of albuminuria, retinopathy at baseline, estimated glomerular filtration rate, HDL-cholesterol, LDL-cholesterol, and intervention trial (hypertension treatment, intensive vs. standard; hypertension trial vs. lipid trial; hyperlipidemia treatment, fibrate vs. no fibrate).

^b^Death from any cause. Covariates include age, sex, race, education, history of smoking, statin uses, insulin uses, previous CVD, history of albuminuria, history of arterial stenosis, retinopathy at baseline, and intervention trial (hypertension treatment, intensive vs. standard; hypertension trial vs. lipid trial; hyperlipidemia treatment, fibrate vs. no fibrate).

^c^Symptomatic, severe hypoglycemia requiring any assistance. Covariates include age, sex, race, education, diabetes duration, living alone or not, insulin uses, previous CVD, retinopathy at baseline, neuropathy at baseline, and estimated glomerular filtration rate.

^d^Bonferroni correction for multiple comparisons.

Ignoring HGI again, total mortality ([Table 2](#T2){ref-type="table"} and [Fig. 3*C*](#F3){ref-type="fig"}) was significantly greater (*P* = 0.02) in the intensive treatment group (7.7%) compared with the standard treatment group (6.3%). There was no interaction between treatment and HGI (*P* = 0.22). HGI subgroup analysis showed that although intensive treatment significantly increased total mortality by 41% (*P* = 0.02) in the high HGI subgroup, it had no effect on mortality in the moderate or low HGI subgroups compared with standard treatment ([Table 2](#T2){ref-type="table"} and [Fig. 3*D*](#F3){ref-type="fig"}).

Ignoring HGI once more, hypoglycemia requiring any assistance was more than threefold greater (*P* \< 0.001) in the intensive treatment group compared with the standard treatment group ([Table 2](#T2){ref-type="table"} and [Fig. 3*E*](#F3){ref-type="fig"}). HGI subgroup analysis showed that the incidence of hypoglycemia was progressively higher in the low, moderate, and high HGI subgroups in the intensive (14.5, 16.8, and 18.8%, respectively) and standard (3.7, 4.5, and 7.5%, respectively) glycemia treatment groups ([Table 2](#T2){ref-type="table"} and [Fig. 3*F*](#F3){ref-type="fig"}). Results were similar for hypoglycemia requiring medical assistance. Sensitivity analyses that included other intervention assignments as stratifying factors in the Cox models, rather than as covariates, showed that the estimated HRs for primary outcomes, total mortality, and hypoglycemia remained stable.

Conclusions {#s9}
===========

Interindividual variation in HbA~1c~ caused by factors other than blood glucose concentration appears to be partly hereditary ([@B21],[@B22]) and has been reported in patients with type 1 diabetes ([@B4]--[@B9],[@B23],[@B24]), with type 2 diabetes ([@B12]--[@B14],[@B25]--[@B27]), and without diabetes ([@B28]--[@B32]). Pediatric patients with type 1 diabetes with higher HGI had higher levels of skin advanced glycation end products ([@B33]). HbA~1c~ levels that are persistently lower or higher than expected among individuals with similar blood glucose levels have been detected in studies where blood glucose was estimated based on FPG ([@B12]), self-monitored mean blood glucose ([@B4],[@B8],[@B9],[@B34]), 7-point mean blood glucose profile sets ([@B6],[@B35]), continuous glucose monitoring ([@B7],[@B11]), or fructosamine ([@B5],[@B26],[@B27]). Unlike other methods for estimating blood glucose, continuous glucose monitoring and fructosamine are relatively free of sampling bias yet produce similar results when assessing interindividual variation in HbA~1c~.

The present studies indicate that subjects in ACCORD with high HGIs had more retinopathy and nephropathy at baseline, as previously reported in the DCCT ([@B6]). The differences in drug use observed between HGI subgroups at baseline could be related to the fact that insulin is more likely to be prescribed for individuals with persistently higher HbA~1c~ (high HGI). Alternatively, different drugs have been shown to influence the quantitative relationship between HbA~1c~ and blood glucose concentration ([@B36]), which could in turn influence the HGI. Higher HGI among black ACCORD participants supports our previous observation of racial variation in HGI in children with type 1 diabetes ([@B8]). Evidence of clinically significant interindividual variation in the quantitative relationship between blood glucose concentration and HbA~1c~ markedly complicates the use of HbA~1c~ for the diagnosis and management of diabetes, especially in mixed-race populations ([@B37]--[@B42]).

Heterogeneity of Treatment Outcomes Among HGI Subgroups in ACCORD {#s10}
-----------------------------------------------------------------

Our present analyses examine the ACCORD glycemia trial through a new lens, namely, the HGI calculated using FPG and HbA~1c~ measured at baseline. As previously reported by the ACCORD investigators, we observed no difference in primary outcomes between the standard and intensive treatment groups despite our use of a slightly different data set (we omitted patients without HbA~1c~ or FPG at baseline) and different statistical methods. HGI subgroup analysis indicated, however, that intensive treatment actually improved primary outcomes in low and moderate HGI participants, a beneficial effect that was offset and masked by the apparently detrimental effects of intensive treatment in the high HGI subgroup. Although total mortality was significantly higher in the intensive treatment group, HGI subgroup analysis showed that the higher mortality associated with intensive treatment was restricted to the high HGI subgroup. Collectively, these observations show that HGI identifies two subpopulations in ACCORD, one that experiences benefits and one that experiences harms from the same intensive glucose-lowering strategy.

The risk for hypoglycemia was greatest in the high HGI subgroup in the standard and intensive treatment groups. More high HGI participants remained above the protocol-mandated HbA~1c~ treatment thresholds after 1 year of standard or intensive treatment. Despite higher mean HbA~1c~, high HGI participants in both glycemia treatment groups had mean FPG values after 1 year that were as low as or lower than those observed in low HGI participants. Collectively, these observations are consistent with our hypothesis that intensive treatment may have inadvertently caused high HGI participants to receive more intensive treatment and could explain the otherwise paradoxical results reported by Miller et al. ([@B3]).

Clinical Implications {#s11}
---------------------

The twin goals of diabetes management are to keep blood glucose levels low enough to limit the development of long-term diabetes complications but high enough to avoid hypoglycemia. After the ACCORD trial reported that intensive treatment increased mortality and hypoglycemia, the American Diabetes Association (ADA) recommended that HbA~1c~ treatment goals for individual patients should be personalized according to characteristics such as age and frequency of hypoglycemia, while also reiterating that lowering HbA~1c~ generally helps prevent or delay long-term complications ([@B43]). Our observations of markedly different outcomes in the different HGI subgroups in response to intensive treatment strongly supports the ADA recommendation for more personalized diabetes management and suggests that HGI could be used to help individualize treatment goals.

Exactly how the results of this study might be used to reinterpret other clinical trials or how the results might be applied in future trial designs or in clinical practice remains to be determined. One reason is that ACCORD participants were older than the general public and selected for elevated risk for CVD. This could explain why the baseline regression equation in ACCORD is markedly different from the linear regression equations reported by studies such as the A1C-Derived Average Glucose (ADAG) study ([@B44]). As such, the results may not be generalizable to other clinical trials or to the general population with diabetes and we cannot recommend the use of the ACCORD regression equation in other populations. Furthermore, only one other study has used FPG to assess the HGI in patients with type 2 diabetes, and these results were only reported in a meeting abstract ([@B12]). All other prior HGI and glycation gap studies in patients with diabetes used some estimate of mean blood glucose or fructosamine. Additional studies of HGI in other clinical trials could help determine how best to use the HGI in clinical practice.

Conclusion {#s12}
----------

Intensive treatment to a low HbA~1c~ target of less than 6% (42 mmol/mol) cannot be recommended for all patients with type 2 diabetes because primary cardiovascular outcomes, total mortality, and hypoglycemia were all adversely affected in high HGI participants in ACCORD. Further studies should determine if the observed beneficial effects of intensive treatment on primary outcomes in low and moderate HGI participants outweigh any detrimental effects that might be caused by the increase in hypoglycemia associated with intensive treatment. Our results confirm that HbA~1c~ is not a one-size-fits-all indicator of blood glucose concentration and suggest that failure to take this into account can result in suboptimal diabetes care.

Clinical trial reg. no. NCT00000620, [clinicaltrials.gov](http://clinicaltrials.gov).
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